Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Symptoms of gastroparesis (e.g., nausea, early satiety, fullness, bloating, upper abdominal pain, retching or vomiting) for at least 3 months prior to Screening~* Body Mass Index (BMI) between 18 and 35 kg/m2, inclusive~* Gastroparesis Cardinal Symptom Index (GCSI-2W) composite score ≥2 and ≤4 at Screening~* Delayed gastric emptying, defined as a gastric emptying half-time (GE t1/2) \> 160 minutes as determined by \[13C\]-octanoate breath test, at Screening~* Upper gastrointestinal (UGI) obstruction ruled out by endoscopy or other imaging reasonably proximal to the diagnosis of gastroparesis~Exclusion Criteria:~* Acute severe gastroenteritis within 2 weeks prior to Screening~* History of gastric outlet obstruction~* Prior history of gastric surgery, including but not limited to gastrectomy, gastric bypass, gastric banding, pyloroplasty, vagotomy, or fundoplication~* Recurrent vomiting, defined as vomiting more than 2 days per week~* Hospitalization for treatment of gastroparesis or complications of diabetes within 4 weeks prior to Screening~* Presence of thyroid dysfunction not controlled by treatment. Subjects with abnormal thyroid stimulating hormone (TSH), hypothyroidism, or hyperthyroidism at Screening~* If Type 1 or Type 2 diabetic, a glycosylated hemoglobin (HbA1c) level \>10% or a glucose \> 250 mg/dL at Screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Sequence 1 (Type: EXPERIMENTAL): 3-way crossover of velusetrag or placebo
- Sequence 2 (Type: EXPERIMENTAL): 3-way crossover of velusetrag or placebo
- Sequence 3 (Type: EXPERIMENTAL): 3-way crossover of velusetrag or placebo
- Sequence 4 (Type: EXPERIMENTAL): 3-way crossover of velusetrag or placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).